The Experts below are selected from a list of 8916 Experts worldwide ranked by ideXlab platform
Antti Vaheri - One of the best experts on this subject based on the ideXlab platform.
-
pathophysiology of a severe case of puumala hantavirus infection successfully treated with Bradykinin Receptor antagonist icatibant
2014Co-Authors: Antti Vaheri, Tomas Strandin, Anne J Jaaskelainen, Olli Vapalahti, Hanna Jarva, Marjaliisa Lokki, Jaakko AntonenAbstract:We recently described a patient with very severe Puumala hantavirus infection manifested by capillary leakage syndrome and shock. He was successfully treated with the Bradykinin Receptor antagonist, icatibant (Antonen et al., 2013). Here we report analysis of the pathophysiology which indicated pronounced complement activation, prolonged leukocytosis, extensive fibrinolysis, circulating histones, and defects in liver function. The patient had an uncommon HLA-phenotype, which may have contributed to the severe course of the disease.
-
a severe case of puumala hantavirus infection successfully treated with Bradykinin Receptor antagonist icatibant
2013Co-Authors: Jaakko Antonen, Ilona Leppanen, Jyrki Tenhunen, Pertti Arvola, Satu Makela, Antti Vaheri, Jukka MustonenAbstract:A patient with severe capillary leakage syndrome caused by a Puumala hantavirus infection was treated with a single dose of icatibant, a Bradykinin Receptor antagonist, with a dramatic positive response. We suggest that this drug should be tested in a larger number of patients with severe hantavirus infection.
Jaakko Antonen - One of the best experts on this subject based on the ideXlab platform.
-
pathophysiology of a severe case of puumala hantavirus infection successfully treated with Bradykinin Receptor antagonist icatibant
2014Co-Authors: Antti Vaheri, Tomas Strandin, Anne J Jaaskelainen, Olli Vapalahti, Hanna Jarva, Marjaliisa Lokki, Jaakko AntonenAbstract:We recently described a patient with very severe Puumala hantavirus infection manifested by capillary leakage syndrome and shock. He was successfully treated with the Bradykinin Receptor antagonist, icatibant (Antonen et al., 2013). Here we report analysis of the pathophysiology which indicated pronounced complement activation, prolonged leukocytosis, extensive fibrinolysis, circulating histones, and defects in liver function. The patient had an uncommon HLA-phenotype, which may have contributed to the severe course of the disease.
-
a severe case of puumala hantavirus infection successfully treated with Bradykinin Receptor antagonist icatibant
2013Co-Authors: Jaakko Antonen, Ilona Leppanen, Jyrki Tenhunen, Pertti Arvola, Satu Makela, Antti Vaheri, Jukka MustonenAbstract:A patient with severe capillary leakage syndrome caused by a Puumala hantavirus infection was treated with a single dose of icatibant, a Bradykinin Receptor antagonist, with a dramatic positive response. We suggest that this drug should be tested in a larger number of patients with severe hantavirus infection.
Anne J Jaaskelainen - One of the best experts on this subject based on the ideXlab platform.
-
pathophysiology of a severe case of puumala hantavirus infection successfully treated with Bradykinin Receptor antagonist icatibant
2014Co-Authors: Antti Vaheri, Tomas Strandin, Anne J Jaaskelainen, Olli Vapalahti, Hanna Jarva, Marjaliisa Lokki, Jaakko AntonenAbstract:We recently described a patient with very severe Puumala hantavirus infection manifested by capillary leakage syndrome and shock. He was successfully treated with the Bradykinin Receptor antagonist, icatibant (Antonen et al., 2013). Here we report analysis of the pathophysiology which indicated pronounced complement activation, prolonged leukocytosis, extensive fibrinolysis, circulating histones, and defects in liver function. The patient had an uncommon HLA-phenotype, which may have contributed to the severe course of the disease.
Olli Vapalahti - One of the best experts on this subject based on the ideXlab platform.
-
pathophysiology of a severe case of puumala hantavirus infection successfully treated with Bradykinin Receptor antagonist icatibant
2014Co-Authors: Antti Vaheri, Tomas Strandin, Anne J Jaaskelainen, Olli Vapalahti, Hanna Jarva, Marjaliisa Lokki, Jaakko AntonenAbstract:We recently described a patient with very severe Puumala hantavirus infection manifested by capillary leakage syndrome and shock. He was successfully treated with the Bradykinin Receptor antagonist, icatibant (Antonen et al., 2013). Here we report analysis of the pathophysiology which indicated pronounced complement activation, prolonged leukocytosis, extensive fibrinolysis, circulating histones, and defects in liver function. The patient had an uncommon HLA-phenotype, which may have contributed to the severe course of the disease.
J F Hess - One of the best experts on this subject based on the ideXlab platform.
-
Generation and Characterization of a Human Bradykinin Receptor B1 Transgenic Rat as a Pharmacodynamic Model
2004Co-Authors: J F Hess, Richard W Ransom, Zhizhen Zeng, Raymond S. L. Chang, Patricia J. Hey, Lee Warren, Charles M. Harrell, Kathryn L. Murphy, Tsing-bau Chen, Patricia MillerAbstract:Antagonists of the B1 Bradykinin Receptor (B1R) offer the promise of novel therapeutic agents for the treatment of inflammatory and neuropathic pain. However, the in vivo characterization of the pharmacodynamics of B1R antagonists is hindered by the low level of B1R expression in healthy tissue and the profound species selectivity exhibited by many compounds for the human B1R. To circumvent these issues, we generated a transgenic rat expressing the human B1R under the control of the neuron-specific enolase promoter. Membranes prepared from whole brain homogenates of heterozygous transgenic rats indicate a B1R expression level of 30 to 40 fmol/mg; there is no detectable B1R expression in control nontransgenic rats. The pharmacological profile of the B1R expressed in the transgenic rat matches that expected of the human, but not the rat Receptor. The mapping of the transgene insertion site to rat chromosome 1 permitted the development of a reliable assay for the identification of homozygous transgenic rats. Significantly, homozygous transgenic rats express 2-fold more B1R than heterozygous animals. Autoradiographic analyses of tissue sections from transgenic rats reveal that the B1R is broadly expressed in both the brain and spinal cord. The human B1R expressed in the transgenic rat functions in an in vitro contractile assay and thus has the potential to elicit a functional response in vivo. Using the humanized B1R transgenic rat, an assay was developed that is suitable for the routine evaluation of a test compound's ability to occupy the human B1R in the central nervous system.
-
expression cloning of a human b1 Bradykinin Receptor
1994Co-Authors: John G Menke, Joseph A Borkowski, Amanda W Derrick, K A Schneck, Kathleen K. Bierilo, David L. Linemeyer, Richard W Ransom, Tanya Macneil, Catherine D Strader, J F HessAbstract:Abstract A cDNA clone encoding a human B1 Bradykinin Receptor was isolated from a human embryonic lung fibroblast cDNA library by expression cloning. The photoprotein aequorin was utilized as an indicator of the ability of the B1 Receptor agonist [des-Arg10]kallidin to mediate Ca2+ mobilization in Xenopus laevis oocytes injected with RNA. A clone was isolated with a 1307-nucleotide insert which contains an open reading frame encoding a 353-amino acid protein with the characteristics of a G-protein-coupled Receptor. The amino acid sequence of the B1 Bradykinin Receptor is 36% identical to the amino acid sequence of the B2 Bradykinin Receptor. The cloned B1 Bradykinin Receptor expressed in mammalian cells exhibits high affinity binding for 3H-labeled [des-Arg10]kallidin and low affinity for Bradykinin. The B1 Receptor antagonist [des-Arg10,Leu9]kallidin effectively displaces 3H-labeled [des-Arg10]kallidin from the cloned Receptor, whereas the B2 Receptor antagonist Hoe-140 (D-Arg0-[Hyp3,Thi5,D-Tic7,Oic8]Bradykinin, where Thi is L-[3-(2-thienyl)alanyl], Tic is D-(1,2,3,4-tetrahydroisoquinolin-3-yl-carbonyl), and Oic is L-[(3aS, 7aS)-octahydroindol-2-yl-carbonyl]) does not. Therefore, the expressed Receptor has the pharmacological characteristics of the B1 Receptor subtype. The availability of both the cloned human B1 and B2 Bradykinin Receptors should allow the elucidation of the relative contributions of these two Receptor subtypes in acute and chronic inflammatory processes.